Chiome Bioscience Inc.

Chiome Bioscience Inc. (株式会社カイオム・バイオサイエンス) is a company based in Shibuya City, Japan, whose stated aim is to bring the light of drug discovery to unmet medical needs. Its headquarters and research laboratories are located in Shibuya-ku, Tokyo, with a drug discovery laboratory at the Teikyo University Biotechnology Research Center in Kawasaki, Kanagawa. The company presents a pipeline of antibody-based programs, including in-house developed products and licensing candidates, spanning oncology and other therapeutic areas.

Chiome Bioscience Inc. is a company located in Shibuya City, Japan. Its headquarters and research laboratories are listed at Sumitomo Fudosan Nishi-shinjuku Bldg. No.6, 3-12-1 Honmachi, Shibuya-ku, Tokyo, and it also lists a drug discovery laboratory at the Teikyo University Biotechnology Research Center in Miyamae-ku, Kawasaki, Kanagawa. The company states that it aims to bring the light of drug discovery to unmet medical needs and describes a governance framework as a company with an audit and supervisory committee. Its disclosed pipeline includes in-house developed products such as CBA-1205 (ADCC enhanced) and CBA-1535 (Tribody™), both in Phase 1 for oncology, as well as outsourced clinical studies such as ADCT-701 (LIV-1205 ADC) targeting DLK-1 in oncology, and licensing candidates and drug discovery projects.

• CBA-1205 (ADCC enhanced)

  In-house developed product targeting DLK-1 in oncology, listed as in Phase 1.

• CBA-1535 (Tribody™)

  In-house developed product targeting 5T4×CD3 in oncology, listed as in Phase 1.

• ADCT-701 (LIV-1205 ADC)

  Outsourced clinical study targeting DLK-1 in oncology (ADC), with the National Cancer Institute as partner.

1. 1株式会社カイオム・バイオサイエンスchiome.co.jp
2. 2パイプライン│株式会社カイオム・バイオサイエンスchiome.co.jp
3. 3コーポレートガバナンス│株式会社カイオム・バイオサイエンスchiome.co.jp
4. 4アクセス│株式会社カイオム・バイオサイエンスchiome.co.jp
5. 5Chiome Bioscience Inc. (Japan)wikidata.org